Saturday, 23 March 2019

Lupin launches Clobazam Oral Suspension to treat seizures

18 February 2019 | News

Lupin’s Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, 2.5mg/mL.

Pharma major Lupin has announced the launch of Clobazam Oral Suspension, 2.5mg/mL, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, 2.5mg/mL. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.

Clobazam Oral Suspension, 2.5mg/mL had annual sales of $253 million in the US (IQVIA MAT December 2018).

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Can collaboration between startups and big life sciences companies offer a disruptive breakthrough?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls